Compare AVO & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVO | XNCR |
|---|---|---|
| Founded | 1983 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 881.9M |
| IPO Year | 2020 | 2013 |
| Metric | AVO | XNCR |
|---|---|---|
| Price | $10.80 | $11.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $17.00 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 977.7K | 653.4K |
| Earning Date | 06-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.92 | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,391,200,000.00 | $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.06 | $4.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.68 | ★ 13.65 |
| 52 Week Low | $10.37 | $6.92 |
| 52 Week High | $15.53 | $18.69 |
| Indicator | AVO | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 22.94 | 44.10 |
| Support Level | $10.37 | $10.83 |
| Resistance Level | $12.21 | $12.87 |
| Average True Range (ATR) | 0.42 | 0.56 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 4.06 | 48.93 |
Mission Produce Inc produces, packs, and distributes mainly Hass avocados to retail, wholesale, and food service customers, offering pre-ripe and ripened fruit tailored to customer specifications through its network of ripening facilities. The Company operates through three segments: Marketing & Distribution, which sources and distributes fruit globally and generates the majority of revenue; International Farming, which owns and operates avocado orchards and supplies fruit mainly to Marketing & Distribution, with operations principally in Peru and Guatemala; and Blueberries, which farms blueberries sold under an exclusive marketing agreement. The Company's operations span Peru, the United States, Guatemala, Mexico, Europe, and Canada.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.